Scaling Back Low-Profitability Businesses and Reviewing the Business Portfolio
First written in FY2016. 7 of 16 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2018: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Other".
- FY2026Ongoing changes in the business mixAnnual report
「In Japan, although the Hospital Care Solutions business was affected by the termination of certain businesses and other factors, the Pharmaceutical Solutions business grew, resulting in a 0.4% increase in revenue from the previous fiscal year.」
Changes in the business mix following the portfolio review continued. While the termination of certain businesses affected the Medical Care Solutions Company’s sales in Japan, Pharmaceutical Solutions offset the impact. - 2026-05-15AdvancedEarnings
「During the current consolidated fiscal year, the Company recorded an impairment loss of ¥4,520 million arising from the termination of an agreement concerning an exclusive distribution right belonging to the Cardiovascular Company, following a review of the partnership structure.」
The Company disclosed the termination of the agreement and the resulting impairment loss following a review of the partnership structure, indicating that the impact of its business portfolio review continued to emerge during the current fiscal year. - FY2026-H1Changes in the business mix following business discontinuationsAnnual report
「In Japan, although revenue from the Hospital Care Solutions business declined following the termination of certain businesses and other factors, the Pharmaceutical Solutions business grew, resulting in a 1.0% year-on-year increase in revenue.」
The termination of certain businesses contributed to the decline in revenue from the Hospital Care Solutions business of the Medical Care Solutions Company, and changes in the business mix following the portfolio review have continued. - FY2025AdvancedAnnual report
「An impairment loss of ¥1,545 million was recognized during the current consolidated fiscal year following the decision to close certain factories belonging to the Cardiovascular Company.」
The business portfolio review progressed, with impairment losses and business restructuring costs recognized in connection with the closure or discontinuation of certain factories in the European Interventional Systems business and the discontinuation of development in the Americas. - FY2025-H1AdvancedAnnual report
「The temporary loss of ¥5,366 million included business restructuring costs of ¥6,594 million and a gain on the sale of land of ¥1,355 million.」
In connection with the review of the business portfolio, business restructuring costs of ¥6,594 million and a gain on the sale of land of ¥1,355 million were recognized during the current interim consolidated fiscal period. - FY2024-Q3Partially offsetting the post-sale revenue declineAnnual report
「In Japan, the decline in revenue from nutritional foods in the Hospital Care Solutions business transferred in the previous fiscal year was offset by strong performance in infusion-related products and the TIS business, resulting in a 1.0% year-on-year increase in revenue.」
Although sales of the relevant products continued to decline after the nutritional foods business was transferred, strong performance in infusion-related products and the TIS business resulted in a 1.0% year-on-year increase in overall sales in Japan. - FY2024-Q2Continued revenue decline after the saleAnnual report
「In Japan, sales of nutritional foods in the Hospital Care Solutions business transferred in the previous fiscal year and thermometers in the Life Care Solutions business declined, resulting in a 2.0% year-on-year decrease in revenue.」
The decline in sales of the nutritional foods business transferred in the previous fiscal year continued to weigh on revenue from the Medical Care Solutions business in Japan in FY2024-Q2. - FY2023AdvancedAnnual report
「For the autologous biologics business, assets held for sale and directly related liabilities were classified as such during the current consolidated fiscal year under the transfer agreement with Global Medical. The disposal group was measured at fair value less costs to sell, and an impairment loss of ¥3,563 million was recognized. The transfer of the business was completed on 11 October 2022.」
The completion of the transfer of the autologous biologics business was confirmed for the full fiscal year. An impairment loss of ¥3.563 billion was recognized in connection with the transfer, and impairment of technology assets also arose following the discontinuation of production of certain products at the Cardiovascular Company. - FY2023-Q3AdvancedAnnual report
「For the autologous biologics business, assets held for sale and directly related liabilities were classified as such during the nine-month period of the current consolidated fiscal year under the transfer agreement with Global Medical. The disposal group was measured at fair value less costs to sell, and an impairment loss of ¥3,589 million was recognized. The transfer of the business was completed on 11 October 2022.」
The transfer of the autologous biologics business was confirmed as completed, and an impairment loss of ¥3.589 billion was recognized in connection with its classification as held for sale. In addition, impairment of technology assets arose following the decision to discontinue production of certain products at the Cardiovascular Company, advancing the portfolio review. - FY2023-Q2AdvancedAnnual report
「Assets and liabilities held for sale in the second quarter of the current consolidated fiscal period were classified as held for sale because decisions had been made to sell the assets relating to the autologous biologics business of the Blood and Cell Technologies Company and the nutritional foods and related products of the Medical Care Solutions Company. For the autologous biologics business, a transfer agreement was signed with Global Medical. The transfer of that business was completed on 11 October 2022. The transfer of the relevant assets was scheduled for early December 2022.」
The autologous biologics business and nutritional foods and related products were classified as held for sale, and a transfer agreement was signed. The transfer of the autologous biologics business was completed on 11 October 2022, while the transfer of the nutritional foods and related products was scheduled for early December 2022. Assets held for sale totaled ¥5,331 million. - FY2018-Q2RestatedAnnual report
「In addition to distributor inventory adjustments for medical equipment products and restrained purchases of infusion and syringe pumps in the first quarter, the Hospital Company's revenue was ¥77.7 billion, down 0.7% year on year, partly due to the impact of supply discontinuations and account rationalization for products in the pharmaceutical and healthcare fields to improve profitability.」
The company continued to cite the termination of supply and rationalization of accounts as measures to review low-profitability products and customers. - FY2018-Q1AdvancedAnnual report
「In addition to discontinuing supplies and rationalizing accounts for products in the pharmaceutical and healthcare fields to improve profitability, the Hospital Company's revenue was ¥36.9 billion, down 3.9% year on year, partly because the alliance business expects more orders in the second half of the current fiscal year than in the second half of the previous fiscal year.」
Regarding the review of low-profitability businesses and products, the company stated that it had terminated supply and rationalized accounts to improve profitability. - FY2017-Q3RestatedAnnual report
「Overseas revenue declined due to the downsizing of low-profitability businesses in Europe and Latin America, as well as the impact of a stronger yen.」
The company continued to describe the downsizing of low-profitability businesses, mainly in Europe and Latin America, as an initiative to improve profitability. - FY2017-Q2RestatedAnnual report
「Overseas, the company worked to improve profitability, including by downsizing low-profitability businesses, mainly in Europe and Latin America.」
The company reiterated its efforts to downsize low-profitability businesses, mainly in Europe and Latin America, and improve profitability. - FY2017-Q1RestatedAnnual report
「Overseas, the company worked to improve profitability by downsizing low-profitability businesses, mainly in Europe, Latin America and parts of Asia.」
The company stated that it was downsizing low-profitability businesses not only in Europe and Latin America but also in parts of Asia, and working to improve profitability. - FY2016First statedAnnual report
「The company reviewed its business portfolio, mainly by downsizing low-profitability businesses in Europe and Latin America, and worked to improve profitability.」
In the Hospital Company’s overseas business, downsizing low-profitability businesses was explicitly identified as a measure to improve profitability, in addition to expanding sales.